You’re listening to a special focus on breast cancer from Advances in Women’s Health, sponsored by Lilly.
Coming to you from the floors of the European Society for Medical Oncology’s Annual Congress in Barcelona, Spain, this is ReachMD, and I’m Dr. Matt Birnholz. This year’s conference features a mountain of new data reports for eager oncology attendees with new and emerging breast cancer treatments taking center stage. Among the most recently anticipated updates concern targeted therapies, such as PARP inhibitors, anti-EGFR drugs, IDH1 blockers and CDK4/6 inhibitors.
While ovarian cancer indications are still drawing the most prominent attention from these small molecule anticancer agents, new data being released at this conference claim initial findings of positive overall survival as well as progression-free survival in patients with triple-negative breast cancers and HER2-negative BRCA-positive breast cancers respectively.
Clinical trials following biologics are also making a big splash at this year’s congress with KEYNOTE 522 and KEYNOTE 119 revealing late-breaking data for heavy-hitter immunotherapies against triple-negative breast cancer. Positive findings on event-free survival from the KEYNOTE 522 trial, which had been under wraps prior to the ESMO Congress, could potentially support future indications for biologics as neoadjuvant therapies for this aggressive form of breast cancer. Meanwhile, the initial reports from KEYNOTE 119 provide a more sobering reminder of the challenges still facing these same biologics where even prominent agents, such as pembrolizumab, struggle to make a dent against metastatic forms of triple-negative breast cancer. But with the ongoing release of heavily anticipated trial outcomes now underway, there is a strong air of excitement and enthusiasm among the conference attendees this year. Likewise, there is new hope on the horizon for breast cancer specialists looking for novel treatment avenues and combinations for their patients with promising data paving the way for additional indication approvals in the months to come.
This has been a coverage highlight from the conference floors of ESMO in Barcelona, Spain. For more therapeutic updates in the breast cancer arena, tune into ReachMD.com where you can join the conversation and Be Part of the Knowledge. I’m Dr. Matt Birnholz. Thanks for listening.
You’ve been listening to this special focus on breast cancer from Advances in Women’s Health. To revisit any part of this discussion and to access other episodes in this series, visit ReachMD.com/Advances-in-Women’s-Health, where you can join the conversation and Be Part of the Knowledge. Thank you for listening.